NCT00861939View on ClinicalTrials.gov

To Demonstrate the Relative Bioavailability of Bupropion HCI 300 mg Extended-Release Tablets Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

April 30, 2004

Study Completion Date

April 30, 2004

Conditions
Depression
Interventions
DRUG

Bupropion HCI 300 mg Extended-Release Tablets EON

DRUG

WELLBUTRIN XL 300 mg Extended-Release Tablets GlaxoSmithKline

Sponsors

Lead Sponsor

Sandoz
All Listed Sponsors
lead

Sandoz

INDUSTRY

NCT00861939 - To Demonstrate the Relative Bioavailability of Bupropion HCI 300 mg Extended-Release Tablets Under Fasting Conditions | Biotech Hunter | Biotech Hunter